To our best knowledge, no comprehensive overview of the evidence for the prognostic value of cardiac biomarkers, especially BNP/NT-proBNP and troponin T and I, on major adverse cardiac events (MACE) in hypertension has been reported, despite the widely accepted and growing interest in the use of circulating plasma biomarkers for risk stratification. This evidence concerns the gene NPPB and Hypertension.